Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1195
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1195 is an investigational mRNA-based vaccine developed by **Moderna**, specifically designed to target the **Epstein-Barr virus (EBV)**. EBV is a ubiquitous herpesvirus that has been strongly linked to the pathogenesis of **Multiple Sclerosis (MS)**, with evidence suggesting it may be a necessary trigger for the disease. mRNA-1195 aims to induce a robust immune response against EBV antigens, potentially preventing the onset of MS or modifying the disease course in affected individuals. The vaccine utilizes Moderna's proprietary **lipid nanoparticle (LNP)** technology to deliver mRNA encoding four EBV glycoproteins (gp350, gH, gL, and gp42), which are involved in viral entry into B cells and epithelial cells. As of 2024, mRNA-1195 is being evaluated in **Phase 2** clinical trials for MS and **Phase 1** trials in healthy participants.
- Other names
- mRNA-1195mRNA1195mRNA 1195
02
Targets
EBV envelope glycoproteins (Epstein-Barr virus envelope glycoproteins)
Beyond the preview
Go deeper on mRNA-1195.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1195.